In a randomized controlled, double-blind phase II trial, saroglitazar ameliorated ALT secretion, insulin resistance, and dyslipidemia significantly in NAFLD/NASH patients (132). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.